
ExpreS²ion Biotechnologies Announces Research License Agreement with the University of Pennsylvania

Horsholm, Denmark, November 8, 2017 – Today, ExpreS²ion Biotechnologies ApS (“ExpreS²ion”), a fully owned subsidiary of ExpreS²ion Biotech Holding AB, announces that University of Pennsylvania, Philadelphia, USA, has signed a Research License Agreement granting University of Pennsylvania the right to conduct research using ExpreS²ion’s proprietary protein expression system, ExpreS².

The Research License Agreement

The Research License Agreement grants University of Pennsylvania, Philadelphia, USA, the right to conduct research using ExpreS²ion’s proprietary ExpreS² system for one year. ExpreS²ion and University of Pennsylvania are not disclosing any terms for the Research License Agreement.

The ExpreS² Platform

ExpreS²ion specialises in solving the toughest protein expression challenges using a fully optimised Schneider 2 (S2) system, based on *Drosophila* (fruit fly) cells, a set of proprietary protein expression vectors, as well as other components. Our highly experienced scientists are specialised in developing cell lines and processes based on our stable S2 protein expression system, ExpreS². One of the advantages of ExpreS² is that it is very robust, meaning that cell lines and processes developed using ExpreS² are highly reproducible. Another advantage is that high yields can be obtained quickly from polyclonal pools without tedious cloning, which is often needed when using mammalian cells. The platform perfectly supports all phases of drug discovery, R&D and manufacturing and S2 cells have been in use for decades in research and clinical trials by a number of companies and research institutions. ExpreS²ion’s scientists have optimised the S2 protein expression system since year 2000 to its current sophistication and established the proprietary ExpreS², which was made commercially available in 2010. It has been widely used to produce many hundreds of different proteins of which some have entered clinical trials. As an example, in October 2016, ExpreS²ion’s collaboration partner, the Jenner Institute of the University of Oxford, initiated a Phase I/IIa clinical study to assess the safety, immunogenicity, and efficacy of the blood-stage *Plasmodium falciparum* malaria antigen RH5.1, which was enabled and produced with ExpreS².

Research and commercial licenses to ExpreS² are available and we aim to position ExpreS² as an early stage process- and production tool for customers and collaboration partners, as well as researchers in academic institutions.

CEO Dr. Steen Klysner comments

“We are pleased that our platform is now part of the R&D and educational toolbox of a strong, highly renowned institution such as University of Pennsylvania, where the advantages of ExpreS² will sustain the innovation and generation of new projects”.

For further information, please contact:

ExpreS²ion Biotechnologies ApS,
Dr. Steen Klysner, CEO
Telephone: +45 2062 9908
E-mail: sk@expres2ionbio.com

About ExpreS²ion

ExpreS²ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. ExpreS²ion’s unique proprietary platform technology, ExpreS², is designed to enable accelerated, cost effective development and robust production of complex proteins for new vaccines and diagnostics. Since founded in 2010, more than 250 proteins involved in e.g. malaria and Zika were produced in collaborations with research institutions and companies with a superior efficiency and success rate. ExpreS²ion also develops competitive virus-like-particle based vaccines through its joint venture AdaptVac, which was founded in 2017.